TW202216690A - Ｃｅｒｅｂｌｏｎ結合化合物、其組合物及使用該等物質之治療方法 - Google Patents
Ｃｅｒｅｂｌｏｎ結合化合物、其組合物及使用該等物質之治療方法 Download PDFInfo
- Publication number
- TW202216690A TW202216690A TW110122966A TW110122966A TW202216690A TW 202216690 A TW202216690 A TW 202216690A TW 110122966 A TW110122966 A TW 110122966A TW 110122966 A TW110122966 A TW 110122966A TW 202216690 A TW202216690 A TW 202216690A
- Authority
- TW
- Taiwan
- Prior art keywords
- mmol
- equiv
- trans
- methyl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043650P | 2020-06-24 | 2020-06-24 | |
| US63/043,650 | 2020-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202216690A true TW202216690A (zh) | 2022-05-01 |
Family
ID=79167578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110122966A TW202216690A (zh) | 2020-06-24 | 2021-06-23 | Ｃｅｒｅｂｌｏｎ結合化合物、其組合物及使用該等物質之治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11560371B2 (https=) |
| EP (1) | EP4171567B1 (https=) |
| JP (1) | JP7781083B2 (https=) |
| KR (1) | KR20230027214A (https=) |
| CN (1) | CN115968293B (https=) |
| AR (1) | AR122726A1 (https=) |
| ES (1) | ES3047718T3 (https=) |
| TW (1) | TW202216690A (https=) |
| WO (1) | WO2021262815A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CR20220630A (es) | 2020-05-09 | 2023-01-23 | Arvinas Operations Inc | Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| KR20230027066A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| TW202535392A (zh) | 2023-12-08 | 2025-09-16 | 美商亞文納營運公司 | 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861432B2 (en) * | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
| CN101032483B (zh) | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN110023297A (zh) * | 2016-07-08 | 2019-07-16 | 詹森药业有限公司 | 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物 |
| CN110317192A (zh) | 2018-03-28 | 2019-10-11 | 上海美志医药科技有限公司 | 一类具有降解雄激素受体活性的化合物 |
| CN113473987B (zh) | 2018-12-19 | 2024-09-03 | 细胞基因公司 | 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法 |
| CN113453681B (zh) | 2018-12-19 | 2024-10-11 | 细胞基因公司 | 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法 |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| KR20230027066A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
-
2021
- 2021-06-23 KR KR1020237002103A patent/KR20230027214A/ko active Pending
- 2021-06-23 JP JP2022578998A patent/JP7781083B2/ja active Active
- 2021-06-23 AR ARP210101738A patent/AR122726A1/es not_active Application Discontinuation
- 2021-06-23 US US17/356,283 patent/US11560371B2/en active Active
- 2021-06-23 ES ES21829558T patent/ES3047718T3/es active Active
- 2021-06-23 CN CN202180043585.3A patent/CN115968293B/zh active Active
- 2021-06-23 EP EP21829558.2A patent/EP4171567B1/en active Active
- 2021-06-23 WO PCT/US2021/038629 patent/WO2021262815A1/en not_active Ceased
- 2021-06-23 TW TW110122966A patent/TW202216690A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4171567B1 (en) | 2025-09-03 |
| CN115968293A (zh) | 2023-04-14 |
| JP2023531495A (ja) | 2023-07-24 |
| CN115968293B (zh) | 2025-08-26 |
| AR122726A1 (es) | 2022-09-28 |
| EP4171567A4 (en) | 2024-07-24 |
| ES3047718T3 (en) | 2025-12-04 |
| JP7781083B2 (ja) | 2025-12-05 |
| US11560371B2 (en) | 2023-01-24 |
| EP4171567A1 (en) | 2023-05-03 |
| US20220002273A1 (en) | 2022-01-06 |
| KR20230027214A (ko) | 2023-02-27 |
| WO2021262815A1 (en) | 2021-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7778095B2 (ja) | セレブロン結合化合物、その組成物及びそれによる治療方法 | |
| JP7781792B2 (ja) | セレブロン結合化合物、その組成物及びそれによる治療方法 | |
| EP4171567B1 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| WO2022272074A1 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| HK40091357B (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| HK40091357A (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| KR20240025613A (ko) | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 | |
| KR20240026946A (ko) | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 | |
| HK40091356B (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| HK40091356A (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| EA047871B1 (ru) | Соединения, связывающие цереблон, композиции на их основе и способы лечения с их применением |